Literature DB >> 18202903

Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease.

M Kobayashi1, T Ohashi, M Sakuma, H Ida, Y Eto.   

Abstract

Fabry disease is an X linked lysosomal storage disorder resulting from deficiency of α-galactosidase A activity. Although disease manifestations in heterozygous females with Fabry disease have been considered to be rare and mild, heterozygous patients with severe symptoms have recently been reported. In this study we focused on the clinical characteristics of Japanese females patients with Fabry disease and analysed data from 36 women. Data on clinical manifestations such as acroparaesthesia, hypohidrosis, angiokeratoma, corneal opacities, proteinuria, end-stage renal disease (ESRD), left ventricular hypertrophy (LVH) and cerebral infarction were obtained by questionnaire; these analysed by the Kaplan-Meier method and compared with the data from Japanese male patients. Eighty-six per cent of female patients had at least one clinical sign of Fabry disease. Their most common symptoms were acroparaesthesia and corneal opacities, and diagnosis was most commonly based on family history. The cumulative incidences of angiokeratoma, corneal opacities, proteinuria, ESRD, LVH and cerebral infarction were significantly lower in female than in male patients. However, corneal opacities, proteinuria and LVH developed progressively in female patients as well as in male patients. The incidence of LVH was especially high in older female patients and the cumulative incidence of LVH in women over 68 years of age was 100%. We consider that the term X-linked 'recessive' is inappropriate for Fabry disease because of the high prevalence of its pathognomonic signs in heterozygous female patients. Careful and long-term evaluation of clinical signs is important in heterozygous females patients with Fabry disease.

Entities:  

Year:  2008        PMID: 18202903     DOI: 10.1007/s10545-007-0740-6

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  9 in total

1.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

2.  Clinical presentation in female patients with Fabry disease.

Authors:  N Guffon
Journal:  J Med Genet       Date:  2003-04       Impact factor: 6.318

3.  Natural history of Fabry disease in females in the Fabry Outcome Survey.

Authors:  P B Deegan; A F Baehner; M-A Barba Romero; D A Hughes; C Kampmann; M Beck
Journal:  J Med Genet       Date:  2005-10-14       Impact factor: 6.318

4.  Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes.

Authors:  C Whybra; C Kampmann; I Willers; J Davies; B Winchester; J Kriegsmann; K Brühl; A Gal; S Bunge; M Beck
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

5.  Cardiac manifestations of Anderson-Fabry disease in heterozygous females.

Authors:  Christoph Kampmann; Frank Baehner; Catharina Whybra; Claudia Martin; Christiane M Wiethoff; Markus Ries; Andreas Gal; Michael Beck
Journal:  J Am Coll Cardiol       Date:  2002-11-06       Impact factor: 24.094

6.  Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.

Authors:  Gabor E Linthorst; Carla E M Hollak; Wilma E Donker-Koopman; Anneke Strijland; Johannes M F G Aerts
Journal:  Kidney Int       Date:  2004-10       Impact factor: 10.612

7.  Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.

Authors:  F Baehner; C Kampmann; C Whybra; E Miebach; C M Wiethoff; M Beck
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

8.  Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.

Authors:  A Mehta; R Ricci; U Widmer; F Dehout; A Garcia de Lorenzo; C Kampmann; A Linhart; G Sunder-Plassmann; M Ries; M Beck
Journal:  Eur J Clin Invest       Date:  2004-03       Impact factor: 4.686

9.  Prevalence of lysosomal storage disorders.

Authors:  P J Meikle; J J Hopwood; A E Clague; W F Carey
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

  9 in total
  13 in total

Review 1.  Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.

Authors:  Saskia M Rombach; Bouwien E Smid; Gabor E Linthorst; Marcel G W Dijkgraaf; Carla E M Hollak
Journal:  J Inherit Metab Dis       Date:  2014-02-04       Impact factor: 4.982

2.  The role of native T1 values on the evaluation of cardiac manifestation in Japanese Fabry disease patients.

Authors:  Ikuko Anan; Toru Sakuma; Eiko Fukuro; Satoshi Morimoto; Ayumi Nojiri; Makoto Kawai; Ken Sakurai; Masahisa Kobayashi; Hiroshi Kobayashi; Hiroyuki Ida; Toya Ohashi; Michihiro Yoshimura; Yoshikatsu Eto; Kenichi Hongo
Journal:  Mol Genet Metab Rep       Date:  2022-03-16

3.  A case of female Fabry disease revealed by renal biopsy.

Authors:  Sae Aratani; Hiroyuki Yamakawa; Shinya Suzuki; Tomoyuki Otsuka; Yukinao Sakai; Akira Shimizu; Shuichi Tsuruoka
Journal:  CEN Case Rep       Date:  2019-09-21

Review 4.  Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review.

Authors:  Louise L C Pinto; Taiane A Vieira; Roberto Giugliani; Ida V D Schwartz
Journal:  Orphanet J Rare Dis       Date:  2010-05-28       Impact factor: 4.123

5.  Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.

Authors:  John Marshall; Karen M Ashe; Dinesh Bangari; KerryAnne McEachern; Wei-Lien Chuang; Joshua Pacheco; Diane P Copeland; Robert J Desnick; James A Shayman; Ronald K Scheule; Seng H Cheng
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

6.  Identification of Cryptic Novel α-Galactosidase A Gene Mutations: Abnormal mRNA Splicing and Large Deletions.

Authors:  Takashi Higuchi; Masahisa Kobayashi; Jin Ogata; Eiko Kaneshiro; Yohta Shimada; Hiroshi Kobayashi; Yoshikatsu Eto; Shiro Maeda; Akira Ohtake; Hiroyuki Ida; Toya Ohashi
Journal:  JIMD Rep       Date:  2016-06-03

7.  Frequency of de novo mutations in Japanese patients with Fabry disease.

Authors:  Masahisa Kobayashi; Toya Ohashi; Sayoko Iizuka; Eiko Kaneshiro; Takashi Higuchi; Yoshikatsu Eto; Hiroyuki Ida
Journal:  Mol Genet Metab Rep       Date:  2014-08-02

Review 8.  Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies.

Authors:  Regina El Dib; Huda Gomaa; Alberto Ortiz; Juan Politei; Anil Kapoor; Fellype Barreto
Journal:  PLoS One       Date:  2017-03-15       Impact factor: 3.240

9.  Massive accumulation of globotriaosylceramide in various tissues from a Fabry patient with a high antibody titer against alpha-galactosidase A after 6 years of enzyme replacement therapy.

Authors:  Kenichi Hongo; Toru Harada; Eiko Fukuro; Masahisa Kobayashi; Toya Ohashi; Yoshikatsu Eto
Journal:  Mol Genet Metab Rep       Date:  2020-07-16

10.  Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.

Authors:  Fernando C Fervenza; Roser Torra; David G Warnock
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.